Project Grant P01AI198881
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant of $763,102 to The Regents of the University of Colorado (University of Colorado-Denver) on May 22, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The five-year research initiative, scheduled for completion on April 30, 2031, will be conducted in Aurora, Colorado, and focuses on investigating novel roles of mucosal tissue eosinophils in the...
- Federal Grant Award Summary The University of Washington received a $445,338 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded on July 23, 2025, with a completion date of June 30, 2027. This award supports research investigating the mechanisms of age-related lung inflammation in pulmonary melioidosis, a frequently fatal tropical infection caused by Burkholderia pseudomallei. The...
- Federal Project Grant Award Summary George Washington University received a $444,920 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective September 1, 2025, through August 31, 2030. This award funds investigator-initiated biomedical research designed to elucidate the role of endogenous retroviruses (ERVs) in the development of type 2-dominated allergic inflammation in the lungs,...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Feinstein Institutes for Medical Research a $460,625 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) on February 10, 2026, with a completion date of January 31, 2028. This award supports investigator-initiated biomedical research focused on understanding the maturation and maintenance of the germinal center niche, specifically examining follicular...
- Federal Grant Award Summary The La Jolla Institute for Immunology received a $764,868 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective April 1, 2026 through March 31, 2031. The research initiative focuses on identifying and characterizing house dust mite (HDM) allergen-specific CD4+ helper T cell subsets to elucidate mechanisms underlying natural tolerance versus allergen...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Washington a Project Grant of $414,305.00 under the Allergy and Infectious Diseases Research program (CFDA 93.855) for research on influenza neuraminidase structure and dynamics. The award, issued on February 19, 2026, with a completion date of January 31, 2028, supports investigator-initiated biomedical research aimed at characterizing structural variation in influenza...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $427,625 Project Grant to The Washington University (Office of Sponsored Research Services) for a two-year research initiative spanning February 4, 2026, through January 31, 2028. This award, funded under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports investigator-initiated biomedical research into the mechanistic roles of calcineurin in regulating CD8+...
- Federal Grant Award Summary Award Details: The National Institute of Allergy and Infectious Diseases (NIAID) awarded Tufts University School of Medicine a Project Grant totaling $1,294,374 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 3, 2025, with a completion date of June 30, 2030. Research Scope: This award funds investigation into the role of heme synthesis in controlling regulatory T cell (Treg) fitness and function, with the objective of developing...
- Federal Grant Award Summary The University of Washington received a $2.31 million Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded February 1, 2026, with completion targeted for January 31, 2030. The award supports fundamental research into the molecular determinants and cellular localization functions of bacterial polysaccharides in Pseudomonas aeruginosa biofilms. The...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded University of Colorado-Denver a Project Grant of $234,000 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on April 23, 2026, with a completion date of March 31, 2028. This award funds research to dissect the transcriptional control of human mucosal-associated invariant T (MAIT) cells, focusing on the roles of transcription factors PLZF and Helios in governing cell...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $2.72 million Project Grant on June 12, 2026, to the University of Washington for a five-year research initiative titled "A Multi-Tissue Temporal Framework for TH2 Responses" (completion date: May 31, 2031). This award falls under the Allergy and Infectious Diseases Research program (CFDA 93.855) and supports investigator-initiated biomedical research on Type 2 immune responses across multiple tissue environments. The research program delivers scientific knowledge and mechanistic insights into how Type 2 immunity is initiated, maintained, and recalled across barrier tissues—specifically the small intestine, skin, large intestine, and lungs. The project comprises four interdependent sub-projects that collectively address neuro-immune circuit regulation, allergic sensitization pathways, inflammatory niche formation, and tissue-resident memory populations. Through harmonized methods and shared resources, the research generates discoveries applicable to understanding both helminth defense mechanisms and chronic allergic disease pathology (including asthma, eczema, and food allergy), while advancing fundamental immunological understanding through cross-tissue comparative analysis and identifying conserved versus tissue-specific principles governing Type 2 inflammatory responses.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $2.7m | 6/12/26 |